Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
Whitehawk Therapeutics signed an option agreement with Hangzhou DAC to access the CPT113 linker-payload technology for up to five new internally developed ADC programs. The deal allows Whitehawk to retain global rights and full program control while selecting targets and sourcing antibodies, with IND submissions expected over the next 12-24 months.
Key figures
- Pipeline expansion
- up to 5 new ADC programs
- Hwk007 dose cohort 1
- 2 mg/kg
- Hwk007 dose cohort 2
- 4 mg/kg
- Hwk016 dose cohort 1
- 2.5 mg/kg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.